Document is current
Any future updates will be listed below
-
Authors
Olsen, Flemming Javier https://orcid.org/0000-0001-9511-8375
Bertelsen, Litten
Vejlstrup, Niels
Bjerregaard, Caroline Løkke
Diederichsen, Søren Zöga
Jørgensen, Peter Godsk
Jensen, Magnus T.
Dahl, Anders
Landler, Nino Emmanuel
Graff, Claus
Brandes, Axel
Krieger, Derk
Haugan, Ketil
Køber, Lars
Højberg, Søren
Svendsen, Jesper Hastrup
Biering-Sørensen, Tor
-
Funding
Funding for this research was provided by:
Innovationsfonden
Region Hovedstaden
Hjerteforeningen (18-R125-A8534-22083)
Aalborg University Talent Management Programme
Arvid Nilssons Fond
Medtronic
Herlev & Gentofte Hospital
Kong Christian den Tiendes Fond
Fru Asta Florida Boldings Mindelegat
Herlev and Gentofte Hospital
Fondsbørsvekselerer Henry Hansen og Hustrus Hovedlegat
Lundbeckfonden
Novo Nordisk Fonden
- License Information
-
More Information
Article History
Received: 15 October 2021
Accepted: 29 December 2021
First Online: 3 January 2022
Declarations
:
: PGJ: Speaker Honorarium: Novo Nordisk and Astra Zeneca. TBS: Steering Committee member: the Amgen financed GALACTIC-HF trial and the Boston Scientific financed LUX-Dx TRENDS trial; Advisory Board: Sanofi Pasteur and Amgen; Speaker Honorarium: Novartis and Sanofi Pasteur; Research grant: GE Healthcare and Sanofi Pasteur. JHS: Advisory board: Medtronic. Research grant and speaker fee from Medtronic in relation to this study. LK: Speakers honorarium from Novo, Novartis, AstraZeneca and Boehringer. SZD: Advisory for Vital Beats. KH: travel and educational grants from Medtronic, Abbott, and BIOTRONIK and speaker honoraria from Boehringer-Ingelheim not related to this work. AB: Research grants from the Region of Southern Denmark, the Region of Zealand, and Theravance. Speaker honorarium from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb. Travel grant from Biotronik. The other authors have no potential conflict of interest to report.
